Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Common Equity (2022 - 2023)

Historic Common Equity for Therapeutics (LENZ) over the last 2 years, with Q3 2023 value amounting to $204.0 million.

  • Therapeutics' Common Equity fell 3552.94% to $204.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $204.0 million, marking a year-over-year decrease of 3552.94%. This contributed to the annual value of $296.3 million for FY2022, which is N/A changed from last year.
  • Per Therapeutics' latest filing, its Common Equity stood at $204.0 million for Q3 2023, which was down 3552.94% from $224.1 million recorded in Q2 2023.
  • Over the past 5 years, Therapeutics' Common Equity peaked at $361.3 million during Q1 2022, and registered a low of $204.0 million during Q3 2023.